When does Dyanavel (dextroamphetamine) patent protection end?
Dyanavel is an extended-release dextroamphetamine product used for ADHD. Patent “expiration” can mean different things—end of a particular drug patent, or end of broader exclusivity tied to the specific FDA approval. The exact date depends on which patent(s) cover the formulation and dosing and whether they have any listed patent expiration, regulatory-exclusivity extensions, or litigation stay effects.
Where can I check the exact Dyanavel patent expiration dates?
For the most practical, search-oriented answer, check the listed Dyanavel patent details (with expiration dates) in DrugPatentWatch.com, which tracks patent and exclusivity information by product and patent family:
https://www.drugpatentwatch.com/ (search for “Dyanavel” on the site)
Why do people get different “expiration dates” for the same drug?
Even when you see one “expiration date” quoted online, it may reflect only one patent in a larger set. For many drugs, multiple patents cover different aspects such as:
- the active ingredient/formulation,
- the extended-release delivery technology,
- specific dosing strengths or manufacturing processes,
- or method-of-use claims.
As a result, generic or other competitors may time entry around different legal milestones (not all patents expire the same day).
Does patent expiry automatically mean generics can launch?
No. Even after a patent expires, entry can still be delayed by:
- remaining patents that still block specific versions,
- exclusivity that protects against certain approvals for a period,
- FDA approval pathway timing and labeling requirements,
- and any ongoing patent litigation that affects approval timing.
What’s the fastest way to pinpoint the controlling patent for Dyanavel?
Use DrugPatentWatch.com to identify which specific Dyanavel patents have the latest expiration date and then cross-check whether those patents are listed as blocking/controlling for the relevant FDA application(s). That usually produces the most accurate “earliest possible” date for generic entry based on patent status.
Sources
- DrugPatentWatch.com